Kim Jin Hee, Yoon Hae-Jee, Choi Yujin, Kim Jin Se, Ju In Gyoung, Eo Hyeyoon, Lee Seungmin, Cho Jun-Young, Park Boyoung Y, Hong Seon-Pyo, Park Hi-Joon, Oh Myung Sook
Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Department of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Eur J Nutr. 2025 Mar 10;64(3):116. doi: 10.1007/s00394-025-03639-4.
Parkinson's disease (PD) disrupts the regulation of neurotransmitters in the brain, causing patients to experience not only motor symptoms but also non-motor symptoms such as depression. 6-shogaol (6S) is a potential neuro-nutraceutical derived from ginger, and is known to ameliorate motor symptoms by suppressing inflammation in PD mice. In this study, we investigated whether 6S can attenuate motor symptoms and depression-like behaviors through neurotransmitter regulation and to elucidate which neurotransmitters are intimately correlated with these effects.
C57BL/6 J mice were injected with 30 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 5 d to induce PD. 6S was administered via oral gavage for 11 d, including the MPTP injection period.
6S alleviated MPTP-induced motor symptoms and depression-like behaviors. MPTP injection decreased the levels of seven neurotransmitters in the striatum and four neurotransmitters in the hippocampus. Administration of 6S increased striatal dopamine, serotonin, and norepinephrine levels and hippocampal dopamine, norepinephrine, serotonin, and γ-aminobutyric acid levels. Moreover, correlation analysis shown that the motor symptom improvement effect of 6S was associated with striatal dopamine, norepinephrine, serotonin, and 5-hydroxyindoleacetic acid levels. The effect of 6S on depressive-like behavior was significantly correlated with striatal dopamine metabolites and serotonin and hippocampal dopamine, norepinephrine, and serotonin. Immunohistochemistry showed that 6S upregulated the expression of the vesicular monoamine transporter 2, which was reduced by MPTP in the striatum and hippocampus.
This study demonstrated that 6S improved motor symptoms and depression-like behaviors by regulating the release of monoamine neurotransmitters.
帕金森病(PD)会扰乱大脑中神经递质的调节,导致患者不仅出现运动症状,还会出现如抑郁等非运动症状。6-姜辣素(6S)是一种源自生姜的潜在神经营养剂,已知其可通过抑制PD小鼠的炎症来改善运动症状。在本研究中,我们调查了6S是否能通过神经递质调节来减轻运动症状和类似抑郁的行为,并阐明哪些神经递质与这些作用密切相关。
给C57BL/6 J小鼠注射30 mg/kg的1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP),持续5天以诱导PD。在包括MPTP注射期在内的11天内,通过口服灌胃给予6S。
6S减轻了MPTP诱导的运动症状和类似抑郁的行为。注射MPTP降低了纹状体中七种神经递质和海马体中四种神经递质的水平。给予6S可提高纹状体多巴胺、血清素和去甲肾上腺素水平以及海马体多巴胺、去甲肾上腺素、血清素和γ-氨基丁酸水平。此外,相关性分析表明,6S对运动症状的改善作用与纹状体多巴胺、去甲肾上腺素、血清素和5-羟吲哚乙酸水平有关。6S对抑郁样行为的作用与纹状体多巴胺代谢物、血清素以及海马体多巴胺、去甲肾上腺素和血清素显著相关。免疫组织化学显示,6S上调了囊泡单胺转运体2的表达,该表达在MPTP作用下在纹状体和海马体中降低。
本研究表明,6S通过调节单胺类神经递质的释放改善了运动症状和类似抑郁的行为。